Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald van Vollenhoven(Amsterdam University Medical Centers), Matthias Schneider(Heinrich Heine University Düsseldorf), Carlos Vasconcelos(Hospital de Santo António), Ann E. Clarke(McGill University), Dimitrios Boumpas(University of Crete), W. Graninger(Medical University of Graz), Anisur Rahman(University College London), Adrian Levitsky(Karolinska Institutet), Alexandre E. Voskuyl(Vrije Universiteit Amsterdam), Anna Jędryka-Góral(National Institute of Geriatrics, Rheumatology and Rehabilitation), Frédéric Houssiau(Cliniques Universitaires Saint-Luc), Elena Zakharova, George Βertsias(University of Crete), Eric F. Morand(Novartis (Switzerland)), Ricard Cervera(University Medical Center of the Johannes Gutenberg University Mainz), Anne Voss(Odense University Hospital), Caroline Gordon(University of Birmingham), Ian N Bruce(University of Manchester), Xavier Mariette(Inserm), N. Costedoat‐Chalumeau(Sorbonne Université), Hendrika Bootsma(University Medical Center Groningen), David Isenberg(UCL Australia), Jozef Rovenský(National Institute of Rheumatic Diseases), David Jayne(University of Cambridge), Roger A. Levy(Universidade do Estado do Rio de Janeiro), Kirsten Lerstrøm, Murat İnanç(Istanbul University), Søren Jacobsen(Copenhagen University Hospital), Thomas Dörner(German Rheumatism Research Centre), Martin Aringer(University Medical Center), Annegret Kuhn(University of Münster), Ronald H. W. M. Derksen(University Medical Center Utrecht), László Czirják(University of Pecs), Sandra Navarra(University of Santo Tomas Hospital), Josef S Smolen(Medical University of Vienna), Asad Zoma(NHS Lanarkshire), Irmgard Neumann(Wilhelminen Hospital), Marta Mosca(University of Pisa)
Cited by 726
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
|Annals of the Rheumatic Diseases|2019|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k